HROW Harrow, Inc. - Common Stock
$39,50
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 10, 2026
Zakres 52 tyg.
$29–$55
42% of range
Ocena Analityków
BUY
14 analysts
Cena Docelowa
$68
+71% upside
P/E (TTM)
-282.1
ROE
-8.4%
Marża Zysku Netto
-1.9%
O Harrow, Inc. - Common Stock Przegląd firmy z Wikipedii
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Czytaj więcej
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary.
Administration and drug pricing advocacy
The company's founder and chief executive officer is Mark L. Baum, a lawyer by training. Baum has been working in the HIV-related pharmacy field since 1999. Baum has been an advocate for drug pricing and patient advocacy, debating former US congressman James Greenwood on this issue at the Oxford Union debating society. In 2016, Baum authored a monograph on drug pricing and has written about pharmaceutical market monopolies in The Wall Street Journal.
Harrow, through its ImprimisRx subsidiary, has sought to create competition for drugs that companies have monopolies through regulatory or other means by marketing new formulations as a compounding pharmacy. This strategy would allow patient access to certain lower cost medication provided, among other conditions, a patient's physician believed such a formulation was best suited for a patient's needs.
In 2015, the company gained international attention when it compounded a pyrimethamine and leucovorin combination formulation which it argued may offer a low-cost, US$1 per pill, "alternative" to Daraprim, a medication which gained public attention after its price in the United States was increased by over 5,000 percent by Martin Shkreli and Turing Pharmaceuticals. In December 2015, Express Scripts accepted the company's product into its formulary.
In 2016, it introduced a lower cost version of tiopronin, and was said to have been working on a version of Mylan's EpiPen. The EpiPen competitor's price target was US$100 for a pair of injectors.
In October 2015, Anthony Principi, a former United States Secretary of Veterans Affairs, was elected to the company's board of directors.
ImprimisRx compounding business
Through its compounding subsidiary ImprimisRx, the company was the first pharmaceutical compounding company to make cGMP ophthalmic eye drops and other sterile compounded products available at a national scale through its FDA-registered outsourcing facility.
ImprimisRx's primary business is that of compounding drugs; that is, combining or altering the formulation of existing drugs to market them to specific populations. As of 2015, the company's business model was driven by development and sale of inexpensive alternatives to off-patent medicines where there was previously only a single manufacturer who could therefore charge outsize prices.
In August 2020, ImprimisRx announced that it was expanding its business beyond compounded drugs and that through a partnership with EyePoint Pharmaceuticals, it would begin to sell Dexycu, an FDA-approved steroid product.
As of 2020, Imprimis operated two pharmaceutical production and distribution facilities, both of which are located in Ledgewood, New Jersey. The company has licenses to operate federally, through the US DEA, and through state pharmacy boards in all 50 of the United States.
Litigation
In 2017, after launching a $49 per month low-cost compounded cyclosporine-A formulation as a potential competitor to Restasis and a glaucoma eye drop program called Simple Drops, the company, alongside Sinceres, became the target of a suit from Allergan for claims connected to supposed false and misleading marketing statements.
The company responded, calling Allergan a "professional litigant" and stating, "Allergan, one of the most powerful Big Pharma companies in the world, has filed this lawsuit against one of the smallest pharmaceutical companies in the world, to snuff out any competition to its high drug price strategies. Allergan, a true Goliath, is bent on ensuring that Americans continue to pay the highest possible prices for its drugs."
During the lawsuit, it was revealed that Allergan engaged in significant lobbying to FDA, state boards of pharmacy, and other federal and state agencies to complain about ImprimisRx. In December 2017, ImprimisRx received a warning letter from the FDA, relaying the agency's determination that the marketing of some of the company's eye drops contained false or misleading claims about efficacy and risks, allegedly in violation of federal law.
After a jury trial, Harrow (then Imprimis Pharmaceuticals) was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan having sought $60 million.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
HROW Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$39.50
Kapitalizacja Rynkowa
$1.47B
P/E (TTM)
-282.1
EPS (TTM)
$-0.14
Przychody (TTM)
$272M
Stopa dywidendy
—
ROE
-8.4%
D/E Dług/Kapitał
—
Zakres 52 tyg.
$29 – $55
HROW Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$272M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
Wolny przepływ pieniężny
$43M
2016-12-31
→
2025-12-31
Marże
-1.9%
2016-12-31
→
2025-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
HROW
Mediana porównawcza
P/E (TTM)
-282.1
31.7
P/S (TTM)
5.4
5.1
P/B
28.0
4.8
Price / FCF (Cena / FCF)
34.2
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
HROW
Mediana porównawcza
Gross Margin (Marża brutto)
75.0%
74.1%
Operating Margin (Marża Operacyjna)
11.2%
—
Net Profit Margin (Marża Zysku Netto)
-1.9%
-0.88%
ROA
-1.3%
-2.9%
ROE
-8.4%
-6.8%
ROIC
218.6%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
HROW
Mediana porównawcza
Current Ratio (Wskaźnik bieżący)
2.2
4.7
Quick Ratio (Wskaźnik Szybkości)
1.9
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
HROW
Mediana porównawcza
Revenue YoY (Przychody R/R)
36.4%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
45.4%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
41.0%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
HROW
Mediana porównawcza
HROW Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
14 analityków
- Mocne kupno 5 35,7%
- Kup 8 57,1%
- Trzymaj 1 7,1%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
8 analityków · 2026-08-18
Mediana
$61.50
Średnia
$67.50
← Poniżej wszystkich celów
$39.50
Niski
$59.00
Wysoki
$88.00
Średni cel
$61.50
+55,7%
Średnia cel
$67.50
+70,9%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-0.18%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $-0.34 | $-0.18 | -0.16% |
| 31 marca 2026 | $-0.74 | $-0.41 | -0.33% |
| 31 grudnia 2025 | $0.17 | $0.38 | -0.21% |
| 30 września 2025 | $0.22 | $0.27 | -0.05% |
| 30 czerwca 2025 | $0.13 | $0.01 | 0.12% |
| 31 marca 2025 | $-0.50 | $-0.05 | -0.45% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| ETON | $457M | — | 104.9% | -5.8% | -18.4% | 53.5% |
| AVLN | — | — | — | — | — | — |
| MAZE | $2.04B | -13.6 | — | — | -598.9% | — |
| INVA | — | 6.1 | 14.7% | — | — | — |
| LBRX | $563M | -7.1 | — | — | -25.5% | — |
| XERS | $1.30B | — | 43.7% | 0.19% | -19.7% | — |
| PAHC | — | 21.5 | 27.4% | 3.7% | 17.8% | 30.9% |
| SPTX | — | — | — | — | — | — |
| ANRO | $568M | -8.1 | — | — | -46.1% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 18
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Cost of Revenue | $68M | $49M | $40M | $25M | $18M | $14M | $17M | $17M | $14M | · | · | · | |
| Gross Profit | $204M | $150M | $91M | $63M | $54M | $34M | $34M | $25M | $13M | $10M | $5M | $567.0K | |
| R&D Expense | $21M | $12M | $7M | $3M | $11M | $2M | $2M | $825.0K | $413.0K | $739.0K | $332.0K | $237.0K | |
| SG&A Expense | $153M | $129M | $83M | $58M | $41M | $31M | $33M | $29M | $25M | $18M | $13M | $8M | |
| Operating Expenses | $174M | $142M | $90M | $61M | $53M | $34M | $39M | $30M | $25M | · | · | · | |
| Operating Income | $31M | $9M | $431.0K | $2M | $2M | $385.0K | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M | |
| Interest Expense | · | · | $21M | $7M | $5M | · | · | · | · | · | · | $3.8K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | $32.4K | |
| Other Non-op | $47.0K | $-185.0K | $-444.0K | $102.0K | $197.0K | $-73.0K | $630.0K | $103.0K | $-884.0K | $2M | $-1M | $29.0K | |
| Pretax Income | $-1M | $-17M | $-24M | $-14M | $-18M | $-3M | $-117.0K | $15M | $-13M | $-19M | · | · | |
| Income Tax | $4M | $161.0K | $701.0K | $75.0K | $133.0K | $4.0K | $8.0K | · | $-935.0K | $-111.0K | · | $3.0K | |
| Net Income | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| EPS (Basic) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | $-0.69 | $-0.13 | $0.01 | $0.67 | $-0.60 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | · | $-0.13 | $0.01 | $0.61 | $-0.60 | · | · | · | |
| Shares (Basic) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | 26,757,451 | 25,895,352 | 25,323,159 | 21,917,570 | 20,027,712 | · | · | · | |
| Shares (Diluted) | 36,760,461 | 35,650,714 | 32,616,777 | 27,460,968 | · | 25,895,352 | 26,466,098 | 23,812,045 | 20,027,712 | · | · | · | |
| EBITDA | $32M | $10M | $1M | $3M | $3M | $2M | $-5M | $-5M | $-12M | $-16M | $-15M | $-10M |
Bilans 27
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $73M | $47M | $74M | $96M | $42M | $4M | $5M | · | $4M | $9M | $3M | $8M | |
| Short-term Investments | · | · | $9M | $6M | $9M | $28M | · | · | · | · | · | · | |
| Receivables | $111M | $116M | $36M | $6M | $4M | $3M | $2M | $2M | $2M | $3M | $840.0K | $81.0K | |
| Inventory | $14M | $11M | $11M | $7M | $4M | $4M | $3M | $2M | $2M | $2M | $1M | $373.0K | |
| Prepaid Expense | $14M | $15M | $10M | $4M | $1M | $2M | $586.0K | $837.0K | $714.0K | $938.0K | $786.0K | $241.0K | |
| Other Current Assets | $2M | $3M | $2M | $118.0K | $92.0K | $190.0K | $105.0K | $125.0K | $124.0K | $106.0K | $119.0K | $35.0K | |
| Current Assets | $212M | $190M | $139M | $118M | $61M | $41M | $36M | $33M | $9M | $15M | $6M | $9M | |
| PP&E (Net) | $3M | $4M | $4M | $3M | $3M | $4M | $5M | $6M | $6M | $7M | $3M | $243.0K | |
| PP&E (Gross) | $15M | $15M | $14M | $13M | $11M | $10M | $11M | $11M | $9M | $9M | $3M | $288.0K | |
| Accum. Depreciation | $12M | $11M | $10M | $9M | $8M | $6M | $5M | $4M | $3M | $1M | $300.0K | $45.0K | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $2M | $2M | $2M | $2M | $332.0K | |
| Intangibles | $175M | $185M | $160M | $24M | $16M | $2M | $2M | $3M | $3M | $3M | $3M | $611.0K | |
| Total Assets | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Accounts Payable | $35M | $39M | $25M | $14M | $6M | $4M | $8M | $6M | $4M | $4M | $3M | $787.0K | |
| Short-term Debt | · | $220M | · | · | · | $4M | $2M | $3M | · | $4M | · | · | |
| Current Liabilities | $96M | $91M | $49M | $19M | $10M | $11M | $12M | $12M | $6M | $10M | $5M | $2M | |
| Capital Leases | $8M | $9M | $7M | $7M | $6M | $7M | $6M | · | $720.0K | $1M | $1.0K | $19.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $936.0K | $1M | · | |
| Total Liabilities | $347M | $320M | $242M | $130M | $87M | $31M | $32M | $25M | $21M | $21M | $16M | $2M | |
| Long-term Debt | $250M | $263M | $247M | $152M | $103M | $20M | · | $23M | $23M | · | · | · | |
| Total Debt | · | · | · | · | · | $3M | $2M | $3M | · | $4M | · | · | |
| Common Stock | $37.0K | $35.0K | $35.0K | $30.0K | $27.0K | $26.0K | $26.0K | $24.0K | $21.0K | $19.0K | $10.0K | $9.0K | |
| Paid-in Capital | $209M | $221M | $205M | $137M | $107M | $105M | $102M | $99M | $91M | $83M | · | · | |
| Retained Earnings | $-157M | $-151M | $-134M | $-109M | $-95M | $-77M | $-74M | $-74M | $-89M | $-77M | $-58M | $-42M | |
| Stockholders' Equity | $52M | $70M | $71M | $28M | $11M | $27M | $28M | $25M | $3M | $6M | $-1M | $8M | |
| Liabilities + Equity | $399M | $389M | $312M | $157M | $98M | $57M | $59M | $49M | $24M | $27M | $14M | $10M | |
| Shares Outstanding | 37,229,159 | 35,622,214 | 35,168,260 | 29,901,530 | 26,902,763 | 25,749,875 | 25,526,931 | 24,339,610 | 20,623,129 | 18,627,915 | 9,755,678 | 9,258,231 |
Przepływy pieniężne 16
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | $1M | $255.0K | $37.0K | |
| Stock-based Comp | $13M | $18M | $16M | $8M | $6M | $3M | $2M | $2M | $3M | $4M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | · | $0 | $-935.0K | $-111.0K | · | · | |
| Amort. of Intangibles | $17M | $12M | $10M | $2M | $161.0K | $167.0K | $209.0K | $235.0K | $364.0K | $351.0K | $355.0K | $48.0K | |
| Other Non-cash | $35M | $-24M | $12M | $7M | $16M | $-2M | · | · | · | · | · | · | |
| Operating Cash Flow | $44M | $-22M | $4M | $2M | $5M | $-1M | $950.0K | $687.0K | $-9M | $-11M | $-11M | $-7M | |
| CapEx | $887.0K | $2M | $1M | $3M | $2M | $862.0K | $1M | $2M | $772.0K | $7M | $-995.0K | $174.0K | |
| Investing Cash Flow | $-5M | $-33M | $-153M | $-2M | $-19M | $-981.0K | $-2M | $-2M | $-961.0K | $-7M | $-5M | $-910.0K | |
| Stock Issued | · | · | $65M | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $-13.0K | |
| Net Stock Activity | · | · | · | $23M | · | · | · | $642.0K | $1M | $212.0K | $404.0K | $-13.1K | |
| Financing Cash Flow | $-13M | $29M | $127M | $54M | $51M | $1M | $-1M | $4M | $5M | $25M | $11M | $599.0K | |
| Net Change in Cash | $26M | $-27M | $-22M | $54M | $38M | $-648.0K | $-2M | $3M | $-5M | $6M | $-6M | $-7M | |
| Taxes Paid | $93.0K | $374.0K | · | $75.0K | $11.0K | $4.0K | $17.0K | $4.0K | $9.0K | $9.0K | $1.0K | $1.0K | |
| Free Cash Flow | $43M | $-24M | $2M | $-892.0K | $3M | $-2M | $-518.0K | $-1M | $-10M | $-4M | $-12M | $-7M | |
| Levered FCF | · | · | $-20M | $-8M | · | · | · | · | · | · | · | · |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% | 70.4% | 67.3% | 60.1% | 49.6% | 50.7% | 46.4% | 34.2% | |
| Operating Margin | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% | 0.79% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| Net Margin | -1.9% | -8.8% | -18.8% | -15.9% | -24.9% | -6.9% | 0.33% | 35.4% | -44.8% | -95.7% | -163.6% | -609.4% | |
| Pretax Margin | -0.50% | -8.7% | -18.2% | -15.8% | -24.7% | -7.0% | -0.24% | 35.4% | -48.3% | · | · | · | |
| EBITDA Margin | 11.7% | 5.1% | 1.1% | 3.6% | 4.4% | 4.6% | -9.4% | -12.6% | -45.4% | -79.6% | -152.6% | -611.2% | |
| ROA | -1.3% | -5.0% | -10.4% | -11.0% | -23.1% | -5.8% | 0.31% | 39.9% | -46.9% | -92.3% | -130.5% | -77.8% | |
| ROE | -8.4% | -24.9% | -49.6% | -72.5% | -93.6% | -12.2% | 0.64% | 117.8% | -265.0% | -756.4% | -470.0% | -87.0% | |
| ROIC | 218.6% | 12.8% | 0.63% | 7.0% | 14.4% | 1.3% | · | · | -431.5% | · | · | · |
Płynność i wypłacalność 4
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 | 3.7 | 3.0 | 2.8 | 1.5 | 1.5 | 1.1 | 5.8 | |
| Quick Ratio | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 | 0.6 | 0.2 | 0.2 | 1.0 | 1.2 | 0.7 | 5.3 | |
| Debt / Equity | · | · | · | · | · | 0.1 | 0.1 | 0.1 | · | 0.6 | · | · | |
| Interest Coverage | · | · | 0.0 | 0.3 | · | · | · | · | · | · | · | -2670.2 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.6 | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | 1.1 | 1.0 | 1.0 | 0.8 | 0.1 | |
| Inventory Turnover | 5.6 | 4.6 | 4.6 | 4.7 | 4.5 | 4.0 | 6.5 | 8.1 | · | · | · | · | |
| Receivables Turnover | 2.4 | 2.6 | 6.1 | 16.5 | 20.3 | 20.9 | 26.1 | 24.0 | 12.0 | 10.6 | 21.1 | 40.8 |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 36.4% | 53.3% | 46.9% | 22.2% | 48.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 45.4% | 40.2% | 38.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 41.0% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $272M | $200M | $130M | $89M | $72M | $49M | $51M | $41M | $27M | $20M | $10M | $2M | |
| Net Income TTM | $-5M | $-17M | $-24M | $-14M | $-18M | $-3M | $168.0K | $15M | $-12M | $-19M | $-16M | $-10M | |
| Market Cap | $1.82B | $1.20B | $394M | $441M | $232M | $177M | $199M | $138M | $35M | $47M | $68M | $69M | |
| Enterprise Value | · | · | · | · | · | $175M | · | · | · | $42M | · | · | |
| P/E | -350.0 | -68.5 | -14.9 | -28.9 | · | -52.8 | 778.0 | 9.3 | -2.8 | · | · | · | |
| P/S | 6.7 | 6.0 | 3.0 | 5.0 | 3.2 | 3.6 | 3.9 | 3.3 | 1.3 | 2.3 | 7.0 | 41.8 | |
| P/B | 34.8 | 17.2 | 5.6 | 16.0 | 20.6 | 6.5 | 7.2 | 5.6 | 13.4 | 7.2 | -48.8 | 8.5 | |
| P / Tangible Book | · | · | · | 124.7 | · | 7.1 | · | · | · | · | · | · | |
| P / Cash Flow | 41.6 | -53.8 | 102.6 | 258.9 | 45.7 | -160.6 | 209.1 | 201.6 | -4.0 | -4.2 | -6.1 | -9.8 | |
| P / FCF | 42.4 | -50.2 | 165.5 | -494.8 | 70.5 | -90.0 | -383.4 | -128.1 | -3.7 | -10.8 | -5.6 | -9.6 | |
| EV / EBITDA | · | · | · | · | · | 77.3 | · | · | · | -2.6 | · | · | |
| EV / FCF | · | · | · | · | · | -89.3 | · | · | · | -9.6 | · | · | |
| EV / Revenue | · | · | · | · | · | 3.6 | · | · | · | 2.1 | · | · | |
| Earnings Yield | -0.29% | -1.5% | -6.7% | -3.5% | · | -1.9% | 0.13% | 10.7% | -35.3% | · | · | · |
Rachunek zysków i strat 17
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $71M | $44M | $89M | $72M | $64M | $48M | $67M | $49M | $49M | $35M | $36M | $34M | $33M | $26M | $20M | $23M | |
| Cost of Revenue | $20M | $17M | $18M | $18M | $16M | $16M | $14M | $12M | $13M | $11M | $11M | $10M | $10M | $8M | $6M | $7M | |
| Gross Profit | $50M | $27M | $71M | $54M | $48M | $32M | $53M | $37M | $36M | $24M | $25M | $24M | $23M | $18M | $14M | $16M | |
| R&D Expense | $8M | $6M | $12M | $3M | $3M | $3M | $5M | $2M | $3M | $2M | $3M | $1M | $1M | $734.0K | $703.0K | $775.0K | |
| SG&A Expense | $53M | $43M | $43M | $36M | $33M | $41M | $35M | $34M | $32M | $29M | $26M | $21M | $20M | $16M | $15M | $15M | |
| Operating Expenses | $61M | $49M | $55M | $39M | $36M | $44M | $40M | $36M | $35M | $31M | $30M | $22M | $21M | $17M | $16M | $16M | |
| Operating Income | $-11M | $-22M | $16M | $15M | $11M | $-11M | $13M | $1M | $2M | $-7M | $-5M | $2M | $2M | $1M | $-2M | $-94.0K | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $5M | · | $6M | $6M | $5M | $2M | $2M | |
| Other Non-op | $0 | · | $7M | $61.0K | $-6.0K | $-7M | $6M | $4.0K | $46.0K | $-7M | $-100.0K | $-195.0K | $-178.0K | $29.0K | · | · | |
| Pretax Income | $-17M | $-28M | $10M | $1M | $5M | $-18M | $6M | $-4M | $-6M | $-14M | $-10M | $-3M | $-4M | $-7M | $1M | $-6M | |
| Income Tax | $0 | $25.0K | · | · | $0 | · | $-514.0K | $20.0K | $655.0K | · | $-535.0K | $2M | $-15.0K | $-288.0K | $0 | $35.0K | |
| Net Income | $-17M | $-28M | $7M | $1M | $5M | $-18M | $7M | $-4M | $-6M | $-14M | $-9M | $-4M | $-4M | $-7M | $1M | $-6M | |
| EPS (Basic) | $-0.46 | $-0.74 | $0.19 | $0.03 | $0.14 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| EPS (Diluted) | $-0.46 | $-0.74 | $0.20 | $0.03 | $0.13 | $-0.50 | $0.19 | $-0.12 | $-0.18 | $-0.38 | $-0.26 | $-0.13 | $-0.14 | $-0.22 | $0.05 | $-0.24 | |
| Shares (Basic) | 37,350,401 | 37,231,321 | -73,001,737 | 37,145,440 | 36,790,306 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| Shares (Diluted) | 37,350,401 | 37,231,321 | -76,794,851 | 38,875,005 | 38,853,855 | 35,826,452 | -71,140,101 | 35,702,200 | 35,618,977 | 35,469,638 | -62,386,827 | 34,255,197 | 30,458,677 | 30,289,730 | -54,418,951 | 27,349,642 | |
| EBITDA | $-11M | $-22M | · | $15M | $12M | $-11M | · | $1M | $2M | $-7M | · | $2M | $2M | $1M | · | $-94.0K |
Bilans 27
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84M | $95M | $73M | $74M | $53M | $67M | $47M | $73M | $71M | $69M | · | $66M | · | · | $96M | $45M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | $7M | · | $8M | $7M | $8M | $6M | $4M | |
| Receivables | $119M | $101M | $111M | $78M | $79M | $77M | $116M | $54M | $52M | $29M | · | $18M | $18M | $12M | $6M | $7M | |
| Inventory | $17M | $16M | $14M | $13M | $12M | $11M | $11M | $10M | $9M | $11M | · | $9M | $9M | $9M | $7M | $5M | |
| Prepaid Expense | $10M | $14M | $14M | $13M | $12M | $15M | $15M | $11M | $7M | $10M | · | $9M | $4M | $4M | $4M | $3M | |
| Other Current Assets | $1M | $1M | $2M | $3M | $3M | $3M | $3M | $1M | $1M | $2M | · | $118.0K | $427.0K | $118.0K | $118.0K | $73.0K | |
| Current Assets | $229M | $226M | $212M | $178M | $155M | $170M | $190M | $147M | $139M | $125M | · | $110M | $60M | $52M | $118M | $64M | |
| PP&E (Net) | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | · | $4M | $4M | $4M | $3M | $3M | |
| PP&E (Gross) | · | · | $15M | $15M | $15M | $15M | $15M | $15M | $14M | $14M | · | $13M | $13M | $13M | $13M | $12M | |
| Accum. Depreciation | · | · | $12M | $12M | $12M | $11M | $11M | $11M | $11M | $10M | · | $10M | $10M | $9M | $9M | $9M | |
| Goodwill | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | · | $332.0K | $332.0K | $332.0K | $332.0K | $332.0K | |
| Intangibles | $176M | $181M | $175M | $172M | $177M | $181M | $185M | $189M | $155M | $157M | · | $163M | $150M | $152M | $24M | $20M | |
| Total Assets | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Accounts Payable | $26M | $26M | $35M | $19M | $23M | $37M | $39M | $25M | $22M | $15M | · | $13M | $18M | $14M | $14M | $14M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $59.0K | · | · | · | · | |
| Short-term Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $102M | $91M | $96M | $65M | $249M | $187M | $91M | $95M | $54M | $42M | · | $19M | $23M | $18M | $19M | $18M | |
| Capital Leases | $7M | $8M | $8M | $8M | $8M | $9M | $9M | $10M | $7M | $7M | · | $7M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $402M | $391M | $347M | $316M | $296M | $308M | $320M | $294M | $248M | $235M | · | $211M | $202M | $196M | $130M | $98M | |
| Long-term Debt | · | $300M | $250M | $347M | $251M | $257M | · | $231M | $236M | $243M | · | $252M | $240M | $244M | · | $98M | |
| Total Debt | · | · | · | $243M | $184M | $108M | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $37.0K | $37.0K | $37.0K | $37.0K | $36.0K | $35.0K | $35.0K | $35.0K | $35.0K | $35.0K | · | $35.0K | $30.0K | $30.0K | $30.0K | $27.0K | |
| Paid-in Capital | $217M | $213M | $209M | $210M | $214M | $226M | $221M | $216M | $212M | $208M | · | $200M | $143M | $138M | $137M | $112M | |
| Retained Earnings | $-201M | $-184M | $-157M | $-163M | $-164M | $-169M | $-151M | $-158M | $-154M | $-147M | · | $-125M | $-120M | $-116M | $-109M | $-111M | |
| Stockholders' Equity | $15M | $29M | $52M | $47M | $50M | $56M | $70M | $58M | $59M | $61M | · | $76M | $22M | $22M | $28M | $1M | |
| Liabilities + Equity | $417M | $420M | $399M | $363M | $345M | $364M | $389M | $352M | $307M | $296M | · | $286M | $224M | $217M | $157M | $99M | |
| Shares Outstanding | 37,484,233 | 37,269,400 | 37,229,159 | 37,034,582 | 36,714,679 | 35,654,171 | 35,622,214 | 35,611,365 | 35,479,492 | 35,380,955 | · | 35,117,621 | 30,276,938 | 30,056,370 | 29,901,530 | 27,074,307 |
Przepływy pieniężne 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $460.0K | $455.0K | $330.0K | $326.0K | $347.0K | $312.0K | $321.0K | $351.0K | $301.0K | $296.0K | $435.0K | $405.0K | $398.0K | $225.0K | $387.0K | $247.0K | |
| Stock-based Comp | $4M | $4M | $4M | $3M | $875.0K | $5M | $5M | $4M | $4M | $4M | $4M | $4M | $5M | $2M | $2M | $2M | |
| Deferred Tax | · | · | · | · | · | · | · | $20.0K | · | · | · | · | $0 | $-288.0K | · | · | |
| Amort. of Intangibles | $6M | $5M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $3M | $2M | $378.0K | $398.0K | |
| Other Non-cash | · | · | · | · | · | $33M | · | · | · | $4M | · | · | · | · | · | · | |
| Operating Cash Flow | $-10M | $-9M | $8M | $17M | $-803.0K | $20M | $-18M | $3M | $-3M | $-5M | $9M | $-1M | $5M | $-8M | $-4M | $-410.0K | |
| CapEx | $491.0K | $194.0K | $341.0K | $210.0K | $166.0K | $170.0K | $555.0K | $604.0K | $344.0K | $92.0K | $194.0K | $520.0K | $250.0K | $496.0K | $878.0K | $1M | |
| Investing Cash Flow | $-534.0K | $-18M | $-5M | $-225.0K | $-293.0K | $-212.0K | $-38M | $-597.0K | $5M | $-110.0K | $-203.0K | $-20M | $-1M | $-131M | $-5.0K | $-1M | |
| Financing Cash Flow | $-466.0K | $49M | $-5M | $5M | $-13M | $23.0K | $30M | $-721.0K | $73.0K | $-809.0K | $-18.0K | $64M | $189.0K | $62M | $55M | $0 | |
| Net Change in Cash | $-11M | $22M | $-1M | $21M | $-14M | $19M | $-25M | $2M | $2M | $-6M | $8M | $43M | $4M | $-77M | $51M | $-1M | |
| Taxes Paid | · | · | $55.0K | $0 | $0 | $38.0K | · | · | · | · | · | · | · | · | $0 | $35.0K | |
| Free Cash Flow | · | $-9M | · | · | · | $19M | · | · | · | $-5M | · | · | · | $-9M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-13M | · | · |
Rentowność 8
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 61.2% | · | 75.3% | 74.5% | 67.5% | · | 75.6% | 74.4% | 69.5% | · | 70.6% | 70.1% | 68.3% | · | 70.5% | |
| Operating Margin | -15.6% | -50.0% | · | 20.6% | 17.9% | -23.5% | · | 2.7% | 3.1% | -20.0% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| Net Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | -37.2% | · | -8.6% | -13.2% | -39.2% | · | -12.8% | -12.6% | -25.4% | · | -28.3% | |
| Pretax Margin | -24.4% | -62.4% | · | 1.4% | 7.8% | · | · | -8.5% | -11.9% | -39.2% | · | -8.3% | -12.7% | -26.6% | · | -28.2% | |
| EBITDA Margin | -15.6% | -50.0% | · | 21.0% | 18.4% | -22.8% | · | 2.7% | 3.1% | -19.2% | · | 5.1% | 7.0% | 4.6% | · | -0.41% | |
| ROA | -4.5% | -7.0% | · | 0.29% | 1.5% | -5.4% | · | -1.3% | -2.4% | -5.3% | · | -2.3% | -2.6% | -4.2% | · | -6.4% | |
| ROE | -53.3% | -64.8% | · | 1.9% | 9.2% | -30.4% | · | -6.3% | -16.0% | -32.9% | · | -11.4% | -30.0% | -41.5% | · | -72.6% | |
| ROIC | -72.4% | -77.0% | · | · | · | · | · | 2.3% | 2.9% | · | · | 3.5% | 10.5% | 5.3% | · | -7.8% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.2 | 2.5 | · | 2.7 | 0.6 | 0.9 | · | 1.5 | 2.6 | 3.0 | · | 5.8 | 2.6 | 2.9 | · | 3.5 | |
| Quick Ratio | 2.0 | 2.1 | · | 2.3 | 0.5 | 0.8 | · | 1.3 | 2.3 | 2.5 | · | 4.9 | 1.1 | 1.1 | · | 3.0 | |
| Debt / Equity | · | · | · | 5.2 | 3.7 | 1.9 | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.3 | · | 0.3 | 0.4 | 0.3 | · | -0.1 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 1.4 | 1.3 | · | 1.5 | 1.5 | 1.4 | · | 1.3 | 1.4 | 1.1 | · | 1.4 | 1.5 | 1.2 | · | 1.5 | |
| Receivables Turnover | 0.7 | 0.5 | · | 1.1 | 1.0 | 0.9 | · | 1.4 | 1.4 | 1.7 | · | 2.7 | 2.7 | 2.9 | · | 4.2 |
Wycena (TTM) 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $250M | $227M | · | $232M | $210M | $181M | · | $167M | $151M | $128M | · | $117M | $106M | $94M | · | $87M | |
| Net Income TTM | $-39M | $-39M | · | $-16M | $-23M | $-42M | · | $-29M | $-29M | $-29M | · | $-22M | $-24M | $-22M | · | $-23M | |
| Market Cap | $1.59B | $1.31B | · | $1.78B | $1.12B | $948M | · | $1.60B | $741M | $468M | · | $505M | $576M | $636M | · | $327M | |
| Enterprise Value | · | · | · | $1.95B | $1.25B | $990M | · | · | · | · | · | · | · | · | · | · | |
| P/E | -40.8 | -32.6 | · | -104.7 | -45.6 | -22.5 | · | -55.5 | -25.2 | -15.2 | · | -19.7 | -22.9 | -27.1 | · | -13.9 | |
| P/S | 6.4 | 5.8 | · | 7.7 | 5.3 | 5.3 | · | 9.6 | 4.9 | 3.6 | · | 4.3 | 5.5 | 6.7 | · | 3.8 | |
| P/B | 104.7 | 45.8 | · | 38.0 | 22.6 | 16.8 | · | 27.6 | 12.7 | 7.7 | · | 6.7 | 25.7 | 29.1 | · | 268.5 | |
| P / Cash Flow | · | -146.1 | · | · | · | 48.2 | · | · | · | -101.1 | · | · | · | -77.4 | · | · | |
| P / FCF | · | -143.1 | · | · | · | 48.6 | · | · | · | -99.2 | · | · | · | -73.0 | · | · | |
| EV / EBITDA | · | · | · | 129.6 | 106.5 | -90.7 | · | · | · | · | · | · | · | · | · | · | |
| EV / FCF | · | · | · | · | · | 50.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | · | · | · | 8.4 | 6.0 | 5.5 | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -2.5% | -3.1% | · | -0.95% | -2.2% | -4.4% | · | -1.8% | -4.0% | -6.6% | · | -5.1% | -4.4% | -3.7% | · | -7.2% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $272M | $200M | $130M | $89M | $72M |
| Marża Brutto % | 75.0% | 75.3% | 69.5% | 71.4% | 74.9% |
| Marża Operacyjna % | 11.2% | 4.4% | 0.33% | 2.2% | 2.2% |
| Zysk netto | $-5M | $-17M | $-24M | $-14M | $-18M |
| Rozwodniony EPS | $-0.14 | $-0.49 | $-0.75 | $-0.51 | — |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 2.2 | 2.1 | 2.8 | 6.3 | 6.2 |
| Wskaźnik Szybkości | 1.9 | 1.8 | 2.4 | 0.6 | 4.8 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $43M | $-24M | $2M | $-892.0K | $3M |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 244 emitenci · $773.6M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 48 (+8 vs poprzedni kw.) | 34 (+4 vs poprzedni kw.) | 74 (+1 vs poprzedni kw.) | 67 (-4 vs poprzedni kw.) | +1.8M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Opaleye Management Inc. | $101 928 000 | 2 400 000 | 13,18% | Akcje |
| Private Capital Management, LLC | $67 899 762 | 1 598 770 | 8,78% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $60 188 994 | 1 417 212 | 7,78% | Akcje |
| Deep Track Capital, LP | $41 153 430 | 969 000 | 5,32% | Akcje |
| STATE STREET CORP | $39 917 043 | 939 888 | 5,16% | Akcje |
| BAMCO INC /NY/ | $34 373 094 | 809 350 | 4,44% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $33 342 270 | 784 905 | 4,31% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31 550 963 | 742 900 | 4,08% | Opcja kupna |
| DIMENSIONAL FUND ADVISORS LP | $26 788 590 | 630 765 | 3,46% | Akcje |
| Divisadero Street Capital Management, LP | $18 650 913 | 439 155 | 2,41% | Akcje |
| CITADEL ADVISORS LLC | $16 622 758 | 391 400 | 2,15% | Opcja kupna |
| RICE HALL JAMES & ASSOCIATES, LLC | $16 459 036 | 387 545 | 2,13% | Akcje |
| Schonfeld Strategic Advisors LLC | $13 574 473 | 319 625 | 1,75% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13 531 367 | 318 610 | 1,75% | Akcje |
| MARSHALL WACE, LLP | $12 157 037 | 286 250 | 1,57% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $11 623 869 | 273 696 | 1,50% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $9 998 202 | 235 418 | 1,29% | Akcje |
| CITADEL ADVISORS LLC | $9 895 510 | 233 000 | 1,28% | Opcja sprzedaży |
| Westside Investment Management, Inc. | $9 473 007 | 223 051 | 1,22% | Akcje |
| FirstWave Capital Management LLC | $9 002 833 | 211 981 | 1,16% | Akcje |
| Blackhawk Capital Partners, LLC | $8 631 645 | 203 241 | 1,12% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $8 074 227 | 190 116 | 1,04% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $7 827 221 | 184 300 | 1,01% | Opcja sprzedaży |
| JANE STREET GROUP, LLC | $7 772 010 | 183 000 | 1,00% | Opcja kupna |
| ROYCE & ASSOCIATES LP | $6 565 310 | 154 587 | 0,85% | Akcje |
| Ikarian Capital, LLC | $5 766 364 | 135 775 | 0,75% | Akcje |
| Advantage Alpha Capital Partners LP | $5 374 624 | 111 553 | 0,69% | Akcje |
| Diametric Capital, LP | $4 965 082 | 116 908 | 0,64% | Akcje |
| WOODMONT INVESTMENT COUNSEL LLC | $4 748 571 | 111 810 | 0,61% | Akcje |
| FIRST TRUST ADVISORS LP | $4 260 378 | 100 315 | 0,55% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $4 146 219 | 97 627 | 0,54% | Akcje |
| 12th Street Asset Management Company, LLC | $3 882 140 | 91 409 | 0,50% | Akcje |
| Lumbard & Kellner, LLC | $3 835 975 | 90 322 | 0,50% | Akcje |
| Steward Partners Investment Advisory, LLC | $3 832 960 | 90 251 | 0,50% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $3 575 210 | 84 182 | 0,46% | Akcje |
| EQUITABLE TRUST CO | $3 371 184 | 79 378 | 0,44% | Akcje |
| BANK OF AMERICA CORP /DE/ | $3 138 533 | 73 900 | 0,41% | Akcje |
| Squarepoint Ops LLC | $3 126 726 | 73 622 | 0,40% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $3 004 668 | 70 748 | 0,39% | Akcje |
| Swiss National Bank | $2 696 845 | 63 500 | 0,35% | Akcje |
| CITADEL ADVISORS LLC | $2 533 888 | 59 663 | 0,33% | Akcje |
| Jefferson Bridge Capital, LLC | $2 427 925 | 57 168 | 0,31% | Akcje |
| CAPTRUST FINANCIAL ADVISORS | $2 395 903 | 56 414 | 0,31% | Akcje |
| Militia Capital Partners, LP | $2 303 000 | 47 000 | 0,30% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $2 288 921 | 53 895 | 0,30% | Akcje |
| GROUP ONE TRADING LLC | $2 085 914 | 49 115 | 0,27% | Akcje |
| LJI Wealth Management, LLC | $2 021 572 | 47 600 | 0,26% | Akcje |
| JANE STREET GROUP, LLC | $2 000 337 | 47 100 | 0,26% | Opcja sprzedaży |
| RENAISSANCE TECHNOLOGIES LLC | $1 894 884 | 44 617 | 0,24% | Akcje |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $1 863 796 | 43 885 | 0,24% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $1 841 542 | 43 361 | 0,24% | Akcje |
| RHUMBLINE ADVISERS | $1 739 772 | 40 965 | 0,22% | Akcje |
| BARD ASSOCIATES INC | $1 716 171 | 40 409 | 0,22% | Akcje |
| BLAIR WILLIAM & CO/IL | $1 693 704 | 39 880 | 0,22% | Akcje |
| LPL Financial LLC | $1 547 267 | 36 432 | 0,20% | Akcje |
| Campbell & CO Investment Adviser LLC | $1 541 066 | 36 286 | 0,20% | Akcje |
| D.A. DAVIDSON & CO. | $1 471 586 | 34 650 | 0,19% | Akcje |
| BOOTHBAY FUND MANAGEMENT, LLC | $1 417 351 | 33 373 | 0,18% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $1 390 549 | 39 437 | 0,18% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $1 375 810 | 39 019 | 0,18% | Akcje |
| STANSBERRY ASSET MANAGEMENT, LLC | $1 360 399 | 32 032 | 0,18% | Akcje |
| GOLDMAN SACHS GROUP INC | $1 330 713 | 31 333 | 0,17% | Akcje |
| Brookstone Capital Management | $1 323 068 | 31 153 | 0,17% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $1 273 208 | 29 979 | 0,16% | Akcje |
| GREAT LAKES ADVISORS, LLC | $1 145 119 | 26 963 | 0,15% | Akcje |
| KORNITZER CAPITAL MANAGEMENT INC /KS | $1 117 556 | 26 314 | 0,14% | Akcje |
| BlackRock, Inc. | $1 115 899 | 26 275 | 0,14% | Akcje |
| Crawford Fund Management, LLC | $1 113 563 | 26 220 | 0,14% | Akcje |
| Bank of New York Mellon Corp | $1 109 571 | 26 126 | 0,14% | Akcje |
| OSAIC HOLDINGS, INC. | $1 066 373 | 25 109 | 0,14% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $1 063 406 | 25 039 | 0,14% | Akcje |
| ExodusPoint Capital Management, LP | $1 029 600 | 24 243 | 0,13% | Akcje |
| Bleakley Financial Group, LLC | $1 022 125 | 24 067 | 0,13% | Akcje |
| Birchview Capital, LP | $1 019 280 | 24 000 | 0,13% | Akcje |
| XTX Topco Ltd | $983 053 | 23 147 | 0,13% | Akcje |
| Focus Partners Wealth | $979 826 | 23 071 | 0,13% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $954 556 | 22 476 | 0,12% | Akcje |
| COMMERCE BANK | $952 602 | 22 430 | 0,12% | Akcje |
| Squarepoint Ops LLC | $925 846 | 21 800 | 0,12% | Opcja sprzedaży |
| VANGUARD ASSET MANAGEMENT, Ltd | $904 399 | 21 295 | 0,12% | Akcje |
| IMC-Chicago, LLC | $886 646 | 20 877 | 0,11% | Akcje |
| FineMark National Bank & Trust | $854 070 | 17 430 | 0,11% | Akcje |
| Sonora Investment Management Group, LLC | $826 191 | 17 148 | 0,11% | Akcje |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $806 930 | 19 000 | 0,10% | Akcje |
| MetLife Investment Management, LLC | $803 023 | 18 908 | 0,10% | Akcje |
| Private Capital Management, LLC | $743 225 | 17 500 | 0,10% | Opcja kupna |
| Round Rock Advisors LLC | $742 418 | 17 481 | 0,10% | Akcje |
| MML INVESTORS SERVICES, LLC | $707 805 | 16 666 | 0,09% | Akcje |
| Lido Advisors, LLC | $700 288 | 16 489 | 0,09% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $692 091 | 16 296 | 0,09% | Akcje |
| Atria Investments, Inc | $683 215 | 16 087 | 0,09% | Akcje |
| UBS Group AG | $672 640 | 15 838 | 0,09% | Akcje |
| BARCLAYS PLC | $672 215 | 15 828 | 0,09% | Akcje |
| SIMPLEX TRADING, LLC | $651 872 | 15 349 | 0,08% | Akcje |
| ARISTEIA CAPITAL, L.L.C. | $651 702 | 15 345 | 0,08% | Akcje |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $633 270 | 14 911 | 0,08% | Akcje |
| VANGUARD GROUP INC | $617 155 | 12 595 | 0,08% | Akcje |
| Grandeur Peak Global Advisors, LLC | $609 572 | 14 353 | 0,08% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $600 441 | 14 138 | 0,08% | Akcje |
| Walleye Partners, LLC | $572 369 | 13 477 | 0,07% | Akcje |
Insiderzy spółki 20 insiderów · 5 dyrektorzy generalni · 11 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark L. Baum | Chief Executive Officer | 10 lutego 2014 A | 1 419 835 | 0 | 0 | $0 |
| Juliet Singh | CEO, Director and President | 18 czerwca 2009 A | 1 954 125 | 0 | 0 | $0 |
| Andrew Boll | VP, Accounting and Reporting | 10 lutego 2014 A | — | 0 | 0 | $0 |
| Joachim Ph Schupp | CHIEF MEDICAL OFFICER | 1 kwietnia 2013 A | — | 0 | 0 | $0 |
| Terry Nida | Chief Business Officer | 26 lutego 2010 A | — | 0 | 0 | $0 |
| Perry J. Sternberg | Dyrektor | 18 czerwca 2026 A | — | 0 | 0 | $0 |
| Adrienne L Graves | Dyrektor | 18 czerwca 2026 A | — | 0 | 0 | $0 |
| Lauren P Silvernail | Dyrektor | 18 czerwca 2026 A | — | 0 | 0 | $0 |
| Peter C Kenny | Dyrektor | 2 października 2013 A | 8 947 | 0 | 0 | $0 |
| Robert J Kammer | Dyrektor | 28 czerwca 2013 A | 931 689 | 0 | 0 | $0 |
| August Shelby Bassani | Dyrektor | 27 czerwca 2013 A | 6 865 | 0 | 0 | $0 |
| Paul Finnegan | Dyrektor | 27 czerwca 2013 A | 6 865 | 0 | 0 | $0 |
| Jeffrey J Abrams | Dyrektor | 27 czerwca 2013 A | 45 927 | 0 | 0 | $0 |
| Stephen G Austin | Dyrektor | 27 czerwca 2013 A | 6 865 | 0 | 0 | $0 |
| DERMASTAR INTERNATIONAL, LLC | Posiadacz 10% | 12 lipca 2012 J | 0 | 0 | 0 | $0 |
| Amir Shojaei | — | 14 sierpnia 2026 M | 0 | 0 | 1 | $-450 000 |
| John N Bonfiglio | — | 20 października 2010 A | 50 000 | 0 | 0 | $0 |
| John T Lomoro | — | 19 czerwca 2009 A | — | 0 | 0 | $0 |
| Lynn C Swann | — | 21 listopada 2008 A | 25 000 | 0 | 0 | $0 |
| Anthony S Thornley | — | 21 listopada 2008 A | 60 900 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 5 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Mark L. Baum ×3 zgłoszenia | 7 kwietnia 2025 | 10,69% | Aneks | — | SEC |
| 27 kwietnia 2021 | — | Pierwotne zgłoszenie | — | SEC | |
| Robert J. Kammer, as Trustee of The Robert J. Kammer Living Trust established 6/1/2000, Robert J. Kammer ×2 zgłoszenia | 30 sierpnia 2016 | — | Pierwotne zgłoszenie | — | SEC |
| Dr. Robert J. Kammer ×2 zgłoszenia | 16 sierpnia 2013 | — | Pierwotne zgłoszenie | — | SEC |
| DermaStar International, LLC ×7 zgłoszenia | 10 sierpnia 2012 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 46 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,47% | 4 670 NS | 30 kwietnia 2026 | N-PORT |
| IWC · iShares Trust | 0,29% | 109 900 SH | 8 sierpnia 2026 | Dziennie |
| IHE · iShares Trust | 0,29% | 118 464 SH | 8 sierpnia 2026 | Dziennie |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,26% | 66 235 NS | 30 kwietnia 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,10% | 2 031 SH | 8 sierpnia 2026 | Dziennie |
| GSSC · Goldman Sachs ETF Trust | 0,10% | 28 159 NS | 31 maja 2026 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0,08% | 48 827 NS | 30 kwietnia 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,08% | 34 722 SH | 8 sierpnia 2026 | Dziennie |
| IWO · iShares Trust | 0,08% | 291 642 SH | 8 sierpnia 2026 | Dziennie |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,07% | 19 636 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 0,07% | 1 370 NS | 31 maja 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,06% | 10 343 NS | 30 kwietnia 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 6 175 NS | 30 kwietnia 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,04% | 2 997 SH | 8 sierpnia 2026 | Dziennie |
| IWM · iShares Trust | 0,04% | 824 976 SH | 8 sierpnia 2026 | Dziennie |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,04% | 186 298 SH | 8 sierpnia 2026 | Dziennie |
| RSSL · Global X Funds | 0,04% | 13 694 NS | 30 kwietnia 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,04% | 123 278 NS | 30 kwietnia 2026 | N-PORT |
| ISCG · iShares Trust | 0,03% | 8 711 SH | 8 sierpnia 2026 | Dziennie |
| SMLF · iShares Trust | 0,03% | 33 778 SH | 8 sierpnia 2026 | Dziennie |
| ITWO · ProShares Trust | 0,03% | 1 486 NS | 31 maja 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,02% | 158 672 NS | 31 maja 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,02% | 18 041 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,02% | 14 677 NS | 30 kwietnia 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 383 679 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,02% | 94 953 SH | 8 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | 0,02% | 1 222 SH | 8 sierpnia 2026 | Dziennie |
| UWM · ProShares Trust | 0,02% | 1 162 NS | 31 maja 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2 264 SH | 8 sierpnia 2026 | Dziennie |
| AVUQ · AMERICAN CENTURY ETF TRUST | 0,01% | 860 NS | 31 maja 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 1 174 NS | 31 maja 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 949 NS | 30 kwietnia 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,01% | 1 223 NS | 31 maja 2026 | N-PORT |
| EBI · RBB Fund Trust | 0,01% | 984 NS | 31 maja 2026 | N-PORT |
| AVUS · AMERICAN CENTURY ETF TRUST | 0,00% | 18 264 NS | 31 maja 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 29 NS | 31 maja 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 50 366 NS | 30 kwietnia 2026 | N-PORT |
| ONEQ · Fidelity Commonwealth Trust | 0,00% | 11 315 NS | 31 maja 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 8 641 NS | 30 kwietnia 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,00% | 1 856 NS | 30 kwietnia 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 11 363 NS | 30 kwietnia 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 45 405 SH | 8 sierpnia 2026 | Dziennie |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 19 602 NS | 31 maja 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 6 962 SH | 8 sierpnia 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1 001 445 SH | 8 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2 637 SH | 8 sierpnia 2026 | Dziennie |